—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Belite Bio Inc ADR (BLTE) — chart, structure and Closelooknet read

The Closelooknet read

Belite Bio is a clinical-stage biopharmaceutical company that develops treatments for diseases with few existing options. Its main candidate, an orally administered drug called Tinlarebant, is in a phase 3 trial meant to protect retinal tissue in patients with Stargardt disease type 1 and geographic atrophy.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for BLTE, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 46/100 · S&P 500 fund at 50, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-02
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 76th percentile of the window, -20.6% over 20 sessions. Factor regime → 2026-11-02
  • Sovereign pressure Index -1.63 · down 2.22 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-02
How it trades on rate days beta 0.62 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How BLTE has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.62 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Belite Bio Inc ADR moved 0.62% on average · correlation 0.11 · higher than 57% of US names
  • Beta, last 3 months 0.64 about the same as over the year
  • On the 10 worst bond days −0.29% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.46% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against BLTE on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Belite Bio Inc ADR

BLTE in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Belite Bio is a clinical-stage biopharmaceutical company that develops treatments for diseases with few existing options. Its main candidate, an orally administered drug called Tinlarebant, is in a phase 3 trial meant to protect retinal tissue in patients with Stargardt disease type 1 and geographic atrophy. The company also has an earlier-stage oral therapy aimed at liver disease and related metabolic conditions still in preclinical work. It was founded in 2016, is based in San Diego, and operates as a subsidiary of a larger biosciences group.
Where it sits in the stack
Belite Bio sits outside Rubin, our index for the AI build-out; it belongs instead to the healthcare and biotechnology corner of our wider coverage universe, unconnected to any chip, data-centre or semiconductor sleeve.
Who it is priced against
Our peer-group data carries no fixed comparison set for this name. The market sometimes reads it alongside Apellis Pharmaceuticals, another developer working on treatments for geographic atrophy, as a rough point of reference.
Why Closelooknet tracks it
Belite Bio holds no seat in Rubin or any other Closelooknet index, and it does not yet carry a Closelooknet score; the diary has not quoted it in any edition to date.
What the diary watches
The diary watches for readouts from the phase 3 trial of Tinlarebant in Stargardt disease and geographic atrophy patients, since a trial result would reset the clinical picture.

Belite Bio Inc ADR (BLTE) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 2 analyst actions on the wire · latest: price target by H.C. Wainwright, 2026-09-08

The Street on this name

Analyst actions and the latest print for BLTE from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target H.C. Wainwright — target 245 from 214 Target raised to $245 from $214 (+27.1% to spot) 2026-09-08
  • Price target Morgan Stanley — target 206 from 201 Target raised to $206 from $201 (+25.6% to spot) 2026-08-14

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What BLTE pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +9.8% in FY2025 39 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-03

Quick answers

What is Belite Bio Inc ADR (BLTE)?

Belite Bio Inc ADR trades as BLTE on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-11-03.

Is BLTE in a Closelooknet index?

Not currently — Belite Bio Inc ADR is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-03.

Where does BLTE trade against its moving averages?

Belite Bio Inc ADR trades 4.7% below its 50-day and 4.2% below its 200-day moving average (1.6% above its 20-day). As of 2026-11-02 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Belite Bio Inc ADR compare with its peers?

Against its peer group (Biotechnology · US), Belite Bio Inc ADR (BLTE) sits 23.2% below its 52-week high, 4.7% below its 50-day average; Halozyme Therapeutics Inc (HALO) is 3.8% below, BeiGene, Ltd. (ONC) is 7.0% below, argenx NV ADR (ARGX) is 18.4% below, as of 2026-11-02. Put any of them next to BLTE in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Belite Bio Inc ADR trade when bond yields rise?

Over the past year Belite Bio Inc ADR had a beta of 0.62 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 57% of US names. On the 10 sessions in which long bonds fell most it moved −0.29% on average, against −0.74% for the S&P 500. As of 2026-11-02; The "How it trades on rate days" block on this page carries the lines.

What does Belite Bio Inc ADR do?

Belite Bio is a clinical-stage biopharmaceutical company that develops treatments for diseases with few existing options. Its main candidate, an orally administered drug called Tinlarebant, is in a phase 3 trial meant to protect retinal tissue in patients with Stargardt disease type 1 and geographic atrophy. The company also has an earlier-stage oral therapy aimed at liver disease and related metabolic conditions still in preclinical work. Our peer-group data carries no fixed comparison set for this name. The market sometimes reads it alongside Apellis Pharmaceuticals, another developer working on treatments for geographic atrophy, as a rough point of reference. (Company snapshot of 2026-09-17.)

Where does Belite Bio Inc ADR sit in the AI build-out?

Belite Bio sits outside Rubin, our index for the AI build-out; it belongs instead to the healthcare and biotechnology corner of our wider coverage universe, unconnected to any chip, data-centre or semiconductor sleeve. Belite Bio holds no seat in Rubin or any other Closelooknet index, and it does not yet carry a Closelooknet score; the diary has not quoted it in any edition to date. (Company snapshot of 2026-09-17.)

Does Belite Bio Inc ADR pay a dividend?

No cash distribution shows in Belite Bio Inc ADR’s price series over the last three years. The share count rose 9.8% over the fiscal year. As of 2026-11-02; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Belite Bio Inc ADR recently?

The most recent analyst action on Belite Bio Inc ADR on the Closelooknet wire is a price target by H.C. Wainwright on 2026-09-08 (target 245 from 214). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for BLTE, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.